Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2019-08-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 386
- Registration Number
- NCT04073537
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04061109
- Locations
- 🇨🇳
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳AnHui Provincial Hospital, Hefei, Anhui, China
🇨🇳FuJian Medical University Union Hospital, Fuzhou, Fujian, China
Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Conditions
- Interventions
- First Posted Date
- 2019-08-19
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04060836
- Locations
- 🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳HeNan Cancer Provincial Hospital, Zhengzhou, Henan, China
🇨🇳AnHui Provincial Hospital, Hefei, Anhui, China
Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 268
- Registration Number
- NCT04056754
- Locations
- 🇨🇳
TongJi medical college of HuaZhong University of Science & Technology Affiliated TongJi Hospital, Wuhan, Hubei, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
🇨🇳The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT04056572
- Locations
- 🇨🇳
Sun-Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 260
- Registration Number
- NCT04009317
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2021-01-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04002622
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
🇨🇳Peking University Third Hospital, Beijin, Beijing, China
🇨🇳Shanghai Tongji Hospital, Shanghai, Shanghai, China
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03996408
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Acral Malignant Melanoma
- First Posted Date
- 2019-06-19
- Last Posted Date
- 2019-10-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT03991975
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijin, Beijing, China
Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2019-06-14
- Last Posted Date
- 2020-03-13
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03986073
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
🇨🇳The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China